EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mapping the causal chain from genetic risk variants to lipid dysmetabolism in Parkinson’s disease

Ruth B De-Paula, Jonggeol Kim, Herve Rhinn, Hiba Saade, Fatima Chavez, Téah Segura, Maria Valeria Lozano, Michelle Etoundi, Karla Silos, Naomi Kass, Viktoriya Korchina, Harshavardhan Doddapaneni und 15 weitere

Brain · 2026

DOI: 10.1093/brain/awag039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2026. Verfasst von Ruth B De-Paula und 26 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative and Computational Biosciences Program, Baylor College of Medicine, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Lipid Metabolism, Serine C-Palmitoyltransferase, Genetic Predisposition to Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Huffington Foundation, McGee Family Foundation, Silverstein Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The molecular pathways linking genetic variants to Parkinson’s disease (PD) onset and progression remain incompletely defined; however, risk alleles in multiple genes, including GBA1, strongly implicate lipid metabolism. To systematically identify causal biomarker signatures, we analysed comprehensive metabolome profiles from blood plasma in 149 PD patients and 150 controls, along with complementary genetic, RNA-sequencing and metabolic data from other available clinical and pathologic cohorts. Using colocalization and summary-data-based Mendelian randomization, we tested whether expression and metabolic quantitative trait loci mediate the association between implicated genetic variants and PD risk. We further integrated differential metabolomics and proteomics from blood and brain to reveal pertinent mechanisms. We show that common PD risk variants at the serine palmitoyltransferase small subunit B (SPTSSB) locus, a key regulator of de novo sphingolipid biosynthesis, are associated with increased SPTSSB brain expression and elevated plasma ceramides. Additional analyses strongly support our hypothesis that a common SPTSSB causal variant is responsible for PD risk as well as the expression and metabolic quantitative trait loci. Multiple sphingolipids and fatty acid derivatives were perturbed in PD, and we identified both unique and shared features with the Alzheimer’s disease metabolome. A PD acylcarnitine signature was further replicated in human post-mortem brain tissue, when comparing those with or without preclinical Lewy body pathology. Integrated analysis of complementary brain proteomic profiles revealed dysregulation of mitochondrial processes dependent on acylcarnitines, including fatty acid beta-oxidation, the tricarboxylic acid cycle and oxidative phosphorylation. Our results identify promising biomarkers and reveal a causal chain linking genetic variation to altered gene/protein expression, lipid dysmetabolism, and the manifestation of PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLipid MetabolismSerine C-PalmitoyltransferaseGenetic Predisposition to DiseaseHumansFemaleMaleBrainQuantitative Trait LociSphingolipidsAgedGenetic VariationMiddle Aged

Stichwörter der Autor:innen

GBA1SPTSSBLewy bodyacylcarnitinefatty acidsphingolipids

Substanzen

Serine C-PalmitoyltransferaseSphingolipids

Autor:innen und Institutionen

  • Quantitative and Computational Biosciences Program, Baylor College of Medicine, Houston, TX 77030, USA.
  • Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.
  • Leal Therapeutics, Worcester, MA 01605, USA.
  • Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA.
  • Nantz National Alzheimer Center, Houston Methodist Neurological Institute and Weill Cornell Medicine, Houston, TX 77030, USA.
  • Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA.

ORCID-Profile: Joseph C Masdeu, Aron S Buchman, Sarah H Elsea, Joshua M Shulman

Förderung

  • Huffington Foundation
  • McGee Family Foundation
  • Silverstein Foundation
  • Houston Methodist Foundation
  • Jan and Dan Duncan Neurological Research Institute
  • Texas Children's Hospital
  • Effie Marie Caine Endowed Chair for Alzheimer's Research
  • Texas Children’s Hospital

Zitieren

APA

De-Paula, R. B., Kim, J., Rhinn, H., Saade, H., Chavez, F., Segura, T., Lozano, M. V., Etoundi, M., Silos, K., Kass, N., Korchina, V., Doddapaneni, H., Venner, E., Masdeu, J. C., Pavlik, V., Yu, M. M., Lin, C. R., Jankovic, J., Buchman, A. S., …, & Shulman, J. M. (2026). Mapping the causal chain from genetic risk variants to lipid dysmetabolism in Parkinson’s disease. Brain. https://doi.org/10.1093/brain/awag039

Vancouver

De-Paula RB, Kim J, Rhinn H, Saade H, Chavez F, Segura T, et al. Mapping the causal chain from genetic risk variants to lipid dysmetabolism in Parkinson’s disease. Brain. 2026. doi:10.1093/brain/awag039

BibTeX
@article{DePaula2026,
  author = {De-Paula, Ruth B and Kim, Jonggeol and Rhinn, Herve and Saade, Hiba and Chavez, Fatima and Segura, Téah and Lozano, Maria Valeria and Etoundi, Michelle and Silos, Karla and Kass, Naomi and Korchina, Viktoriya and Doddapaneni, Harshavardhan and Venner, Eric and Masdeu, Joseph C and Pavlik, Valory and Yu, Melissa M and Lin, Chi-Ying R and Jankovic, Joseph and Buchman, Aron S and Muzny, Donna and Gibbs, Richard A and Elsea, Sarah H and Abeliovich, Asa and Lansbury, Peter and Vanegas-Arroyave, Nora and Shaw, Chad A and Shulman, Joshua M},
  title = {Mapping the causal chain from genetic risk variants to lipid dysmetabolism in Parkinson’s disease},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awag039}
}
Kostenlos starten →